The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection
Scott C Ritchie, Peter Wurtz, Artika P Nath, Gad Abraham, Aki S Havulinna, Liam G Fearnley, Antti-Pekka Sarin, Antti J Kangas, Pasi Soininen, Kristiina Aalto, Ilkka Seppala, Emma Raitoharju, Marko Salmi, Mikael Maksimow, Satu Mannisto, Mika Kahonen, Markus Juonala, Samuli Ripatti, Terho Lehtimaki, Sirpa Jalkanen Show all
Cell Systems | CELL PRESS | Published : 2015
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by Australian Heart Foundation Career Development Fellowship
Awarded by Academy of Finland
Awarded by Novo Nordisk Fonden
This study was supported by funding from National Health and Medical Research Council of Australia (NHMRC) grant APP1062227. M.I. was supported by an NHMRC and Australian Heart Foundation Career Development Fellowship (#1061435). S.R. was supported by an Australian Postgraduate Award and a PhD student top-up award from Victorian Life Sciences Computation Initiative (VLSCI). This study was further supported by the Strategic Research Funding from the University of Oulu, the Sigrid Juselius Foundation, the Academy of Finland (grants 141136), the Yrjo Jahnsson Foundation, the Emil Aaltonen Foundation, and the Finnish Diabetes Research Foundation. The Cardiovascular Risk in Young Finns Study is supported by the Finnish Foundation for Cardiovascular Research; Oulu, Helsinki, Kuopio, Tampere, and Turku University Central Hospital Medical Funds; the Paavo Nurmi Foundation; the Juho Vainio Foundation; the Finnish Cultural Foundation; and the Finnish Funding Agency for Technology and Innovation. M.J. was supported by the Paulo Foundation, Maud Kuistila Foundation, and Finnish Medical Foundation. The DILGOM Study and the National FINRISK Study are supported by the Academy of Finland (grants 139 and 635). The quantitative serum NMR metabolomics platform and its development has been supported by the Academy of Finland, TEKES-the Finnish Funding Agency for Technology and Innovation, the Sigrid Juselius Foundation, the Novo Nordisk Foundation, the Finnish Diabetes Research Foundation, the Paavo Nurmi Foundation, and the strategic and infrastructural research funding from the University of Oulu, as well as by the British Heart Foundation, the Wellcome Trust, and the Medical Research Council, UK. P.W., A.J.K., P.S., and M.A.-K. are shareholders of Brainshake Ltd., a company offering NMR-based metabolite profiling. P.W., A.J.K., P.S., and J.K. report employment relation for Brainshake Ltd.